CD70 expression patterns in renal cell carcinoma

Human Pathology

Volumn 43, Issue 9, 2012, Pages 1394-1399

  Jilaveanu, Lucia B ^a   Sznol, Joshua ^a   Aziz, Saadia A ^a   Duchen, Dylan ^a   Kluger, Harriet M ^a   Camp, Robert L ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD70; Renal cell carcinoma; Therapeutic targets

Indexed keywords

CD70 ANTIGEN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; ONCOCYTOMA; PAPILLOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SARCOMATOID CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD70; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864290155     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.10.014     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
3. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
4. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
5. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
6. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
7. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
8. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
9. J.D. Wolchok, and R.J. Motzer Management of renal cell carcinoma Oncology (Williston Park) 14 2000 29 34 [discussion 34-6, 39]
10. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141 (Pubitemid 41702632)
11. J. Borst, J. Hendriks, and Y. Xiao CD27 and CD70 in T cell and B cell activation Curr Opin Immunol 17 2005 275 281 (Pubitemid 40692662)
12. R.Q. Hintzen, S.M. Lens, and G. Koopman CD70 represents the human ligand for CD27 Int Immunol 6 1994 477 480 (Pubitemid 24087241)
13. R.Q. Hintzen, S.M. Lens, and M.P. Beckmann Characterization of the human CD27 ligand, a novel member of the TNF gene family J Immunol 152 1994 1762 1773 (Pubitemid 24075708)
14. S.M. Lens, K. Tesselaar, and M.H. van Oers Control of lymphocyte function through CD27-CD70 interactions Semin Immunol 10 1998 491 499 (Pubitemid 28564378)
15. + T cells for IL-12-induced Th1 cell development Int Immunol 19 2007 713 718 (Pubitemid 47078715)
16. K.V. Prasad, Z. Ao, and Y. Yoon CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein Proc Natl Acad Sci U S A 94 1997 6346 6351
17. S. Jacquot, T. Kobata, and S. Iwata CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling J Immunol 159 1997 2652 2657 (Pubitemid 127681283)
18. R.Q. Hintzen, S.M. Lens, and K. Lammers Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation J Immunol 154 1995 2612 2623
19. + T cells J Immunol 174 2005 710 717 (Pubitemid 40094264)
20. K. Junker, W. Hindermann, and F. von Eggeling CD70 - a new tumor specific biomarker for renal cell carcinoma J Urol 173 2005 169
21. T. Hishima, M. Fukayama, and Y. Hayashi CD70 expression in thymic carcinoma Am J Surg Pathol 24 2000 742 746 (Pubitemid 30253513)
22. M.C. Ryan, H. Kostner, and K.A. Gordon Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75 Br J Cancer 103 2010 676 684
23. J. Wischhusen, G. Jung, and I. Radovanovic Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma Cancer Res 62 2002 2592 2599 (Pubitemid 34462739)
24. S.M. Lens, P. Drillenburg, and B.F. den Drijver Aberrant expression and reverse signalling of CD70 on malignant B cells Br J Haematol 106 1999 491 503 (Pubitemid 29450677)
25. J. Finke, S. Ferrone, and A. Frey Where have all the T cells gone? Mechanisms of immune evasion by tumors Immunol Today 20 1999 158 160 (Pubitemid 29172275)
26. J. Diegmann, K. Junker, and I.F. Loncarevic Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes Neoplasia 8 2006 933 938 (Pubitemid 44706243)
27. K. Junker, W. Hindermann, and F. von Eggeling CD70: a new tumor specific biomarker for renal cell carcinoma J Urol 173 2005 2150 2153 (Pubitemid 40675271)
28. P.J. Adam, J.A. Terrett, and G. Steers CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding Br J Cancer 95 2006 298 306 (Pubitemid 44187590)
29. J. Diegmann, K. Junker, and B. Gerstmayer Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry Eur J Cancer 41 2005 1794 1801 (Pubitemid 41132643)
30. I.S. Grewal CD70 as a therapeutic target in human malignancies Expert Opin Ther Targets 12 2008 341 351 (Pubitemid 351419427)
31. H.M. Kluger, S.F. Siddiqui, and C. Angeletti Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells Lab Invest 88 2008 962 972
32. E. Oflazoglu, I.J. Stone, and K. Gordon Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker Clin Cancer Res 14 2008 6171 6180
33. J.A. McEarchern, L.M. Smith, and C.F. McDonagh Preclinical characterization of SGN-70, a humanized antibody directed against CD70 Clin Cancer Res 14 2008 7763 7772